Steven Crouse Sells Shares of OmniAb, Inc. (OABI)
Steven Crouse sold 20,000 shares of OmniAb, Inc. on June 17, 2026.
Key Points
- Steven Crouse sold 20,000 shares of OmniAb, Inc. on June 17, 2026, with the stock trading at $2.34.
- OmniAb, Inc. operates in the biotechnology sector with a market cap of about $339.2 million and a 52-week range of $1.30 to $2.79.
- Peers like BlackRock and Geode Capital adjusted their positions in OmniAb, while analysts from RBC Capital and Benchmark maintain a 'buy' rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Steven Crouse sold 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI). The transaction did not involve any monetary value as the shares were sold at a price of $0.00, a common occurrence in certain insider transactions. The stock is currently trading at $2.34.
What Changed in Steven Crouse's OmniAb, Inc. Position
Steven Crouse's recent sale of 20,000 shares of OmniAb, Inc. reflects a reduction in his holdings. The transaction, which took place on June 17, 2026, was not part of a planned trading program. The shares were sold under a transaction code "M", indicating a specific type of insider sale.
Other Institutional Activity in OmniAb, Inc.
In recent institutional activity, BlackRock, Inc. increased its holdings in OmniAb by 41,900 shares, bringing its total to 8,106,881 shares valued at approximately $12.7 million. Geode Capital Management, LLC also added 202,887 shares, resulting in a total of 2,925,579 shares worth about $4.6 million. Conversely, Cadian Capital Management, LP reduced its stake by 277,825 shares, leaving it with 4,157,129 shares valued at around $6.5 million.
OmniAb, Inc. Stock Down 47.7%
Shares of OmniAb, Inc. are currently trading at $2.34 on the NasdaqGM. The company has a market capitalization of approximately $339.2 million and a forward P/E ratio of -7.26, indicating that it is not currently profitable. The stock's 52-week range spans from $1.30 to $2.79. OmniAb's 50-day moving average is $1.97, while its 200-day moving average stands at $1.80. The company's financial health is reflected in a current ratio of 4.80 and a quick ratio of 4.55, with a debt-to-equity ratio of 7.49.
$OABI stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
OmniAb, Inc. reported revenues of $28.9 million with a modest revenue growth of 2.5%. However, the company posted a net margin of -187.6% and a return on equity of -20.3%, indicating ongoing challenges in profitability. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at OmniAb, Inc.
On June 17, 2026, several insiders were active at OmniAb, Inc. Jennifer Cochran bought 40,000 shares and sold 20,000 shares. Carolyn Bertozzi purchased 40,000 shares and sold 20,000 shares. John Higgins also bought 20,000 shares. These transactions were not part of planned trading programs.
Analysts Set New Price Targets
Analyst firms have maintained a positive outlook on OmniAb, Inc. On August 7, 2025, RBC Capital maintained its "buy" rating with a price target of $3.00. Benchmark reiterated its "buy" rating with a target of $6.00 on May 12, 2025. The consensus among analysts is a "buy" recommendation, with an average price target of $7.33 based on six opinions.
About OmniAb, Inc.
OmniAb, Inc. is a biotechnology company based in EmeryVille, California. It specializes in licensing discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to aid in the discovery of therapeutics. The company's platform utilizes transgenic animals to create optimized antibody candidates. OmniAb was founded in 2012 and is led by CEO Mr. Matthew W. Foehr.
Bottom Line
Steven Crouse's sale of 20,000 shares of OmniAb, Inc. is a notable insider transaction, although it was not part of a planned sale. Investors often watch insider activity for signals about company sentiment. As a biotechnology firm, OmniAb operates in a challenging market, reflected in its financial metrics. The recent institutional and analyst activities suggest continued interest and varied outlooks on the company's future performance.
Get OmniAb, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OABI, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.